Year None202120202019201820172016 Date Latest Press Release July 31, 2018 Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection June 4, 2018 Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ May 30, 2018 Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference May 24, 2018 Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock May 23, 2018 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock May 16, 2018 Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) May 11, 2018 Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results April 17, 2018 Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 April 2, 2018 Eiger BioPharmaceuticals to Participate in Conferences in April March 26, 2018 Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
